Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate ...

Dr. Anthony Fauci on Tuesday said that there's a chance that Moderna's COVID-19 booster shot may not have FDA and CDC approval by the White House's Sept. 20 target date, though he expects that ...

(Reuters) -Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, overshadowing lower-than-expected second-quarter loss and sending ...

(Reuters) -Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by robust Spring COVID booster demand and aggressive cost cuts. The ...

Shares fell over 6% in premarket trading on Friday. Net loss narrowed to $825 million, or $2.13 per share. Operating expenses dropped 27% to $1.1 billion. Moderna has lowered the high end of its 2025 ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc GSK in a phase III ...

Moderna announced that its seasonal flu vaccine mRNA-1010 demonstrated 26.6% relative vaccine efficacy compared with standard approved flu vaccines in a phase 3 efficacy trial in adults aged 50 and up ...

A former Senior Publishing Editor on the Dow Jones Newswires team at The Wall Street Journal, Aaron earned a Bachelor's degree in Economics from the University of Michigan and a Master's in Journalism ...

Moderna, Inc. (NASDAQ:MRNA) shares soared to the top of the S&P 500 gainers in early afternoon trading on May 20, surging by 11%. The rise followed the U.S. Food and Drug Administration’s (FDA) ...

[BRIEFING.COM] The S&P 500 (-0.52%) is today's worst-performing average, down now about 30 points. Meanwhile, Moderna (MRNA 28.50, +2.11, +8.00%) is outperforming after FDA leaders signaled support ...